Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

doi:10.1200/JCO-25-00157

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2025

Gillani Riaz, Shulman David S, DelRocco Natalie J, Klega Kelly, Han Ruxu, Krailo Mark D, Slack Jonathan C, Tanhaemami Mohammad, Ward Abigail, Bainer Victoria, Ricker Cora, Sparks Josee, Bailey Kelly M, Reed Damon R, DuBois Steven G, Leavey Patrick, Mascarenhas Leo, Grohar Patrick J, Church Alanna J, Crompton Brian D, Janeway Katherine A

Abstract excerpt

PURPOSE: Identifying discrete subgroups associated with treatment response and resistance in localized Ewing sarcoma (EWS) remains a challenge. The primary objective of the Children's Oncology Group (COG) biology study AEWS18B1-Q was to molecularly characterize patients with localized EWS on prospective modern-day trials. PATIENTS AND METHODS: We analyzed clinical and molecular features from patients with...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bone Neoplasms

Share to Cohesins

Share to DNA Copy Number Variations

Share to Infant

Share to Prognosis

Share to Sarcoma, Ewing

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41183255
DOI: 10.1200/JCO-25-00157
PMCID: PMC12614438

Genes

STAG2
TP53

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Characterization Informs Prognosis in Patients With Localized Ewing Sarcoma: A Report From the Children's Oncology Group.PMID 41183255Read ↗

Molecular characterization informs prognosis in patients with localized Ewing sarcoma: A report from the Children’s Oncology GroupSemantic proximity Read ↗

Genomic landscape of Ewing sarcoma: a pooled analysis of 538 cases and clinicopathological correlationSemantic proximity Read ↗

Risk stratification by somatic mutation burden in Ewing sarcomaSemantic proximity Read ↗

Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations.Semantic proximity Read ↗

The genomic landscape of pediatric Ewing sarcoma.Semantic proximity Read ↗

The genomic landscape of the Ewing Sarcoma family of tumors reveals recurrent STAG2 mutation.Semantic proximity Read ↗

Ewing and Ewing-like-sarcoma tumoroid biobank reveals distinct drug sensitivities: translocation makes the differenceSemantic proximity Read ↗

Sequencing Overview of Ewing Sarcoma: A Journey across Genomic, Epigenomic and Transcriptomic LandscapesSemantic proximity Read ↗

Multidirectional Cellular Plasticity in Ewing Sarcoma Reveals a Tumor–CAF Continuum and Novel Immunotherapeutic TargetsSemantic proximity Read ↗

Breakthrough Technologies Reshape the Ewing Sarcoma Molecular Landscape.Semantic proximity Read ↗

Single-Cell RNA Sequencing of Ewing Sarcoma Tumors Demonstrates Transcriptional Heterogeneity and Clonal EvolutionSemantic proximity Read ↗

Characterization of transcriptional heterogeneity and novel therapeutic targets using single cell RNA-sequencing of primary and circulating Ewing sarcoma cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.